- Home
- MTZ vs ILMN Comparison
MTZ vs ILMN Comparison
Compare MTZ & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTZ
- ILMN
- Stock Information
- Founded
- MTZ 1929
- ILMN 1998
- Country
- MTZ United States
- ILMN United States
- Employees
- MTZ N/A
- ILMN N/A
- Industry
- MTZ Water Sewer Pipeline Comm & Power Line Construction
- ILMN Medical Specialities
- Sector
- MTZ Industrials
- ILMN Health Care
- Exchange
- MTZ Nasdaq
- ILMN Nasdaq
- Market Cap
- MTZ 13.6B
- ILMN 15.3B
- IPO Year
- MTZ N/A
- ILMN 2000
- Fundamental
- Price
- MTZ $198.90
- ILMN $120.74
- Analyst Decision
- MTZ Strong Buy
- ILMN Hold
- Analyst Count
- MTZ 22
- ILMN 15
- Target Price
- MTZ $221.86
- ILMN $114.93
- AVG Volume (30 Days)
- MTZ 1.1M
- ILMN 1.9M
- Earning Date
- MTZ 10-30-2025
- ILMN 10-30-2025
- Dividend Yield
- MTZ N/A
- ILMN N/A
- EPS Growth
- MTZ 270.77
- ILMN N/A
- EPS
- MTZ 4.20
- ILMN 4.46
- Revenue
- MTZ $13,762,473,000.00
- ILMN $4,288,000,000.00
- Revenue This Year
- MTZ $15.02
- ILMN N/A
- Revenue Next Year
- MTZ $9.93
- ILMN $2.74
- P/E Ratio
- MTZ $48.03
- ILMN $26.90
- Revenue Growth
- MTZ 12.99
- ILMN N/A
- 52 Week Low
- MTZ $99.70
- ILMN $68.70
- 52 Week High
- MTZ $224.03
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- MTZ 44.15
- ILMN 69.72
- Support Level
- MTZ $197.97
- ILMN $94.00
- Resistance Level
- MTZ $224.03
- ILMN $124.08
- Average True Range (ATR)
- MTZ 9.23
- ILMN 4.99
- MACD
- MTZ -1.34
- ILMN 2.79
- Stochastic Oscillator
- MTZ 26.12
- ILMN 89.09
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.